Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LongeveronLGVN +1.40%45 3-Year ROIIC % is 128.03 as of Dec. 2025. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,323 Biotechnology companies, Longeveron ranks better than 80.42% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Longeveron's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 128.03%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Longeveron's 3-Year ROIIC % or its related term are showing as below:
LGVN's 3-Year ROIIC % is ranked better than 80.42% of 1323
companies
in the Biotechnology industry
Industry Median: -4.85
vs LGVN: 128.03
Longeveron (NAS:LGVN) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Longeveron 3-Year ROIIC % Related Terms
Longeveron 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Longeveron's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LGVN vs MRKR, PLUR, VYNE: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Longeveron's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longeveron 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longeveron's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Longeveron's 3-Year ROIIC % falls into.
Longeveron's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -23.287 (Dec. 2025) - -18.043 (Dec. 2022) )
/
( 5.505 (Dec. 2025) - 9.601 (Dec. 2022) )
=
-5.244
/
-4.096
=
128.03%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Longeveron (LGVN) has a 3-Year ROIIC % of 128.03 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Longeveron and its competitors. According to the industry distribution chart, Longeveron ranks #259 out of 1323 companies in the Biotechnology industry, placing it in the top 19.6%.
Is Longeveron's 3-Year ROIIC % too high?
Longeveron's current 3-Year ROIIC % is 128.03. Based on the distribution chart, Longeveron ranks #259 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's 3-Year ROIIC % compare to MRKR and PLUR?
According to the Biotechnology industry distribution chart, Longeveron ranks #259 out of 1323 companies for 3-Year ROIIC %. This places Longeveron in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Longeveron and its competitors. Longeveron's current 3-Year ROIIC % is 128.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current 3-Year ROIIC % is 128.03. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Longeveron (LGVN), the current 3-Year ROIIC % is 128.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longeveron (LGVN) Overvalued in 2026?
Based on GuruFocus' analysis, Longeveron stock appears to be overvalued.
The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38.
GuruFocus considers Longeveron to be Significantly Overvalued.
Key valuation signals for LGVN:
3-Year ROIIC %: 128.03
GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score
Get the complete analysis for LGVN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LGVN has been successfully added to your 
